Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

June 30, 2013

Conditions
Adult Brain TumorAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
Interventions
PROCEDURE

conventional surgery

Undergo surgery

DRUG

tandutinib

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

Tissue samples

Correlative studies

Trial Locations (9)

21287

Johns Hopkins University, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

30322

Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00379080 - Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | Biotech Hunter | Biotech Hunter